嘉和生物－Ｂ(06998.HK)公布，中國國家藥品監督管理局已正式受理鹽酸來羅西利片聯合來曲唑治療既往未經過系統性抗腫瘤治療的激素受體陽性、人表皮生長因子受體2陰性晚期乳腺癌患者的新藥上市許可申請。
鹽酸來羅西利片是由公司與美國G1 Therapeutics共同開發的一款用於治療乳腺癌的高選擇性口服型CDK4/6抑制劑。
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- Welcome RewardsOpen an account and get up to HKD1600!
- Enjoy limited-time 5%+5% returns on Cash PlusInvest any amount and enjoy a 5% average return on Cash Plus + 5% welcome reward
- Join Futubull Membership ProgramUnlock 11 Premier Benefits
- Referral PromotionBring a friend and collect up to HK$600 in rewards
- Learn PremiumAnalyst 1V1 online teaching
- Stock TransferSwitch to Futu and get up to HK$7,000 in rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
- Headlines
- 嘉和生物(06998.HK)鹽酸來羅西利片新藥上市許可申請獲受理
嘉和生物(06998.HK)鹽酸來羅西利片新藥上市許可申請獲受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.